Skip to content

US · LENZ · BIOTECHNOLOGY

LENZ Therapeutics, Inc. (LENZ) intrinsic value and stock valuation

$2.97as of 2026-11-21 · Mkt cap 168.06M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

LENZ Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values LENZ with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LENZ’s statements →

LENZ Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Solana Beach, CA 92075 lenz-tx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$19.1M
20192025
Net income
-$-82.13M
20192025
Free cash flow
-$-70M
20192025
Total equity
$284.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$19.1M$0.00$0.00$15M$0.00
Operating income-$-91.14M-$-58.61M-$-72.43M-$-10.48M-$-60.44M
Net income-$-82.13M-$-49.77M-$-69.97M-$-10.81M-$-70.76M
EPSd-$-2.85M-$-2.34M-$-8.59M-$-1.38M-$-8.54M
Operating cash flow-$-69.17M-$-59.39M-$-60.38M-$-87.98M-$-52.85M
Capital expenditure-$-830K-$-470K-$-30K-$-6.59M-$-5.74M
Free cash flow-$-70M-$-59.86M-$-60.41M-$-94.57M-$-58.59M
Total assets$305.9M$215.3M$70.4M$47M$18.3M
Total debt$810K$1.38M$330K$250K$0.00
Net debt-$-24.36M-$-18.78M-$-34.81M-$-44.19M-$-18.31M
Total equity$284.3M$204.1M-$-92.71M-$-24.17M-$-14.21M
Cash and short-term investments$292.4M$209M$65.8M$44.4M$18.3M
Income statement
20252024202320222021
Revenue$19.1M$0.00$0.00$15M$0.00
Cost of revenue$700K$60K$0.00$0.00$730K
Gross profit$18.4M-$-60K$0.00$15M-$-730K
Research and development expenses$18.7M$29.8M$59.5M$21.1M$37.9M
Selling, general and administrative expenses$90.9M$28.8M$12.9M$4.36M$21.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$109.5M$58.6M$72.4M$25.5M$59.7M
Cost and expenses$110.2M$58.6M$72.4M$25.5M$60.4M
Interest income$9.76M$8.55M$2.19M$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$290K$60K$10K$10K$730K
Ebitda-$-81.34M-$-49.71M-$-70.13M-$-10.46M-$-70.03M
Operating income-$-91.14M-$-58.61M-$-72.43M-$-10.48M-$-60.44M
Total other income/expenses, net$9.51M$8.84M$2.28M$20K-$-10.32M
Income before tax-$-81.62M-$-49.77M-$-70.15M-$-10.46M-$-70.76M
Income tax expense$500K$0.00-$-180K$350K$0.00
Net income-$-82.13M-$-49.77M-$-69.97M-$-10.81M-$-70.76M
Weighted average shares outstanding$28.8M$21.3M$8.15M$7.84M$8.29M
Weighted average diluted shares outstanding$28.8M$21.3M$8.15M$7.84M$8.29M
Balance sheet
20252024202320222021
Cash and short-term investments$292.4M$209M$65.8M$44.4M$18.3M
Net receivables$2.43M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$301.4M$211.9M$67.2M$46.6M$18.3M
Property, plant and equipment, net$1.92M$1.99M$370K$280K$10K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$4.46M$3.39M$3.13M$310K$10K
Total assets$305.9M$215.3M$70.4M$47M$18.3M
Accounts payable$4.17M$4.26M$5.71M$4.75M$460K
Short-term debt$470K$570K$140K$100K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$21.2M$10.4M$18.5M$9.5M$1.25M
Long-term debt$350K$810K$190K$150K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$350K$810K$144.6M$61.6M$31.3M
Capital lease obligations$810K$1.38M$330K$250K$0.00
Total liabilities$21.5M$11.2M$163.1M$71.1M$32.6M
Common stock$0.00$0.00$10K$10K$0.00
Retained earnings-$-227.14M-$-145.01M-$-95.25M-$-25.28M-$-14.47M
Accumulated other comprehensive income (loss)$240K$200K$10K-$-1.05M$0.00
Total equity$284.3M$204.1M-$-92.71M-$-24.17M-$-14.21M
Total investments$267.2M$188.9M$30.7M$237.5M$0.00
Total debt$810K$1.38M$330K$250K$0.00
Net debt-$-24.36M-$-18.78M-$-34.81M-$-44.19M-$-18.31M
Cash flow statement
20252024202320222021
Net income-$-82.13M-$-49.77M-$-69.97M-$-101.05M-$-70.76M
Depreciation and amortization-$-3.12M$60K$10K$8.35M$730K
Stock-based compensation$12.6M$6.37M$1.34M$0.00$0.00
Change in working capital$3.25M-$-13.09M$9.41M-$-7.21M-$-2.5M
Accounts receivable-$-330K$0.00$0.00$0.00$0.00
Inventory-$-4.28M$0.00$0.00$0.00$0.00
Accounts payable-$-90K-$-4.28M$860K$190K$1.82M
Net cash provided by operating activities-$-69.17M-$-59.39M-$-60.38M-$-87.98M-$-52.85M
Investments in property, plant and equipment-$-830K-$-470K-$-30K-$-6.59M-$-5.74M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-75.67M-$-154.48M-$-29.62M-$-241.86M-$-5.74M
Common stock issued$149.8M$79.5M$200K$680K$417.2M
Common stock repurchased$0.00$0.00$0.00-$-80K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$149.8M$199M$80.7M$600K$417.5M
Net change in cash$4.91M-$-14.87M-$-9.3M-$-329.25M$357.2M
Cash at end of period$25.2M$20.3M$35.1M$47.7M$377M
Operating cash flow-$-69.17M-$-59.39M-$-60.38M-$-87.98M-$-52.85M
Capital expenditure-$-830K-$-470K-$-30K-$-6.59M-$-5.74M
Free cash flow-$-70M-$-59.86M-$-60.41M-$-94.57M-$-58.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About LENZ Therapeutics, Inc.

        LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

        CEO
        Evert Schimmelpennink
        Employees
        152
        Beta
        1.62

        Explore

        Frequently asked questions

        What is the intrinsic value of LENZ Therapeutics, Inc. (LENZ)?

        InvestorsCraft does not currently publish an intrinsic value for LENZ. How the IC value is calculated.

        Is LENZ undervalued?

        InvestorsCraft does not publish an undervaluation signal for LENZ at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.